JP2011528372A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011528372A5 JP2011528372A5 JP2011518900A JP2011518900A JP2011528372A5 JP 2011528372 A5 JP2011528372 A5 JP 2011528372A5 JP 2011518900 A JP2011518900 A JP 2011518900A JP 2011518900 A JP2011518900 A JP 2011518900A JP 2011528372 A5 JP2011528372 A5 JP 2011528372A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- compound
- compound according
- branched
- linear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 50
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 125000004122 cyclic group Chemical group 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000004982 dihaloalkyl group Chemical group 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 208000032841 Bulimia Diseases 0.000 claims description 4
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 229910052739 hydrogen Chemical group 0.000 claims description 4
- 239000001257 hydrogen Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Chemical group 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical group [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 4
- 229910052717 sulfur Chemical group 0.000 claims description 4
- 239000011593 sulfur Chemical group 0.000 claims description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
- 125000004952 trihaloalkoxy group Chemical group 0.000 claims description 4
- 125000004385 trihaloalkyl group Chemical group 0.000 claims description 4
- 208000028017 Psychotic disease Diseases 0.000 claims description 3
- 206010027175 memory impairment Diseases 0.000 claims description 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 2
- TUVJCVZTAVSNKA-UHFFFAOYSA-N 5-(azepan-1-yl)-n-(5-pyridin-4-yl-1h-pyrazol-3-yl)pentanamide Chemical compound C1=C(C=2C=CN=CC=2)NN=C1NC(=O)CCCCN1CCCCCC1 TUVJCVZTAVSNKA-UHFFFAOYSA-N 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 206010033664 Panic attack Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 208000022531 anorexia Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 230000001713 cholinergic effect Effects 0.000 claims description 2
- 230000003920 cognitive function Effects 0.000 claims description 2
- 206010061428 decreased appetite Diseases 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- IDQINVZEHVHNKA-UHFFFAOYSA-N n-[5-(1-ethylindol-3-yl)-1h-pyrazol-3-yl]-4-pyrrolidin-1-ylbutanamide Chemical compound C12=CC=CC=C2N(CC)C=C1C(=NN1)C=C1NC(=O)CCCN1CCCC1 IDQINVZEHVHNKA-UHFFFAOYSA-N 0.000 claims description 2
- HAOYPPBZLQMFRB-UHFFFAOYSA-N n-[5-(1h-indol-5-yl)-1h-pyrazol-3-yl]-5-piperidin-1-ylpentanamide Chemical compound C=1C(C=2C=C3C=CNC3=CC=2)=NNC=1NC(=O)CCCCN1CCCCC1 HAOYPPBZLQMFRB-UHFFFAOYSA-N 0.000 claims description 2
- ULVWYOLWRHJRGA-UHFFFAOYSA-N n-[5-(5-methylpyridin-3-yl)-1h-pyrazol-3-yl]-4-piperidin-1-ylbutanamide Chemical compound CC1=CN=CC(C=2NN=C(NC(=O)CCCN3CCCCC3)C=2)=C1 ULVWYOLWRHJRGA-UHFFFAOYSA-N 0.000 claims description 2
- PODSWXCZBZIQRU-UHFFFAOYSA-N n-[5-(6-methylpyridin-3-yl)-1h-pyrazol-3-yl]-4-piperidin-1-ylbutanamide Chemical compound C1=NC(C)=CC=C1C1=CC(NC(=O)CCCN2CCCCC2)=NN1 PODSWXCZBZIQRU-UHFFFAOYSA-N 0.000 claims description 2
- MUFOLRMJGLDINZ-UHFFFAOYSA-N n-[5-(furan-2-yl)-1h-pyrazol-3-yl]-5-piperidin-1-ylpentanamide Chemical compound C=1C(C=2OC=CC=2)=NNC=1NC(=O)CCCCN1CCCCC1 MUFOLRMJGLDINZ-UHFFFAOYSA-N 0.000 claims description 2
- 230000007514 neuronal growth Effects 0.000 claims description 2
- 208000019906 panic disease Diseases 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 208000020016 psychiatric disease Diseases 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 208000020685 sleep-wake disease Diseases 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 201000009032 substance abuse Diseases 0.000 claims description 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 C*c1cc(-c2n[n]c(NC(CCC*3CCCCC3)=O)c2)cnc1 Chemical compound C*c1cc(-c2n[n]c(NC(CCC*3CCCCC3)=O)c2)cnc1 0.000 description 3
- XEWVWHPAIRHOCN-UHFFFAOYSA-N NC1=CC2C1=C2 Chemical compound NC1=CC2C1=C2 XEWVWHPAIRHOCN-UHFFFAOYSA-N 0.000 description 2
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 description 2
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 description 2
- RXDLNISRGKTTCU-UHFFFAOYSA-N CC(C)(C)c1ccc(-c2n[nH]c(NC(CCCN3CCCC3)=O)c2)[s]1 Chemical compound CC(C)(C)c1ccc(-c2n[nH]c(NC(CCCN3CCCC3)=O)c2)[s]1 RXDLNISRGKTTCU-UHFFFAOYSA-N 0.000 description 1
- MPCGNOSPLBENQI-CZCUMCSCSA-N CC(C)(C)c1ccc(C(/C=C(\N)/NC(CCCN2CCCCC2)=O)=N)[s]1 Chemical compound CC(C)(C)c1ccc(C(/C=C(\N)/NC(CCCN2CCCCC2)=O)=N)[s]1 MPCGNOSPLBENQI-CZCUMCSCSA-N 0.000 description 1
- AZDGONBLNUKYRG-UHFFFAOYSA-N CC(C)(CC(Nc([nH]nc1-c(cc2)cc3c2nccc3)c1F)=O)CN1CCCC1 Chemical compound CC(C)(CC(Nc([nH]nc1-c(cc2)cc3c2nccc3)c1F)=O)CN1CCCC1 AZDGONBLNUKYRG-UHFFFAOYSA-N 0.000 description 1
- MYNCUIQJVHNXGN-UHFFFAOYSA-N CC(C)(CC(Nc([nH]nc1-c2cc(F)cnc2)c1F)O)CN1CCCC1 Chemical compound CC(C)(CC(Nc([nH]nc1-c2cc(F)cnc2)c1F)O)CN1CCCC1 MYNCUIQJVHNXGN-UHFFFAOYSA-N 0.000 description 1
- LKWAGWGTSPXSAU-UHFFFAOYSA-N CC(C)(CC1CCCC1)CC(Nc([nH]nc1-c(cn2)ccc2OCC2CN(CC(C)(C)CC(Nc([nH]nc3-c4cc(OC)cnc4)c3F)=O)CC2)c1F)=O Chemical compound CC(C)(CC1CCCC1)CC(Nc([nH]nc1-c(cn2)ccc2OCC2CN(CC(C)(C)CC(Nc([nH]nc3-c4cc(OC)cnc4)c3F)=O)CC2)c1F)=O LKWAGWGTSPXSAU-UHFFFAOYSA-N 0.000 description 1
- SXWRLSZSEFFVHE-UHFFFAOYSA-N CC(CCC(Nc1cc(-c2cnc(C(F)(F)F)c(C)c2)n[nH]1)=O)N(CC1)CC1c(c(C)c1)ncc1-c1n[nH]c(NC(CCCN2CCCC2)=O)c1 Chemical compound CC(CCC(Nc1cc(-c2cnc(C(F)(F)F)c(C)c2)n[nH]1)=O)N(CC1)CC1c(c(C)c1)ncc1-c1n[nH]c(NC(CCCN2CCCC2)=O)c1 SXWRLSZSEFFVHE-UHFFFAOYSA-N 0.000 description 1
- UOCQCKQAVHDNSY-UHFFFAOYSA-N CCCC(Nc([nH]nc1-c2cc(cccc3)c3nc2)c1F)=O Chemical compound CCCC(Nc([nH]nc1-c2cc(cccc3)c3nc2)c1F)=O UOCQCKQAVHDNSY-UHFFFAOYSA-N 0.000 description 1
- HLNRRPIYRBBHSQ-UHFFFAOYSA-N CCCN1CCCC1 Chemical compound CCCN1CCCC1 HLNRRPIYRBBHSQ-UHFFFAOYSA-N 0.000 description 1
- WTVULSSIYJTPKF-UHFFFAOYSA-N CC[n](ccc1c2)c1ccc2-c1n[nH]c(NC(CCCN2CCCC2)=O)c1 Chemical compound CC[n](ccc1c2)c1ccc2-c1n[nH]c(NC(CCCN2CCCC2)=O)c1 WTVULSSIYJTPKF-UHFFFAOYSA-N 0.000 description 1
- BLGGXPBHLUZEDW-UHFFFAOYSA-N CC[n]1c(cccc2)c2c(-c2n[nH]c(NC(CCCN3CCC(CC[n]4c5cc(-c6n[nH]c(NC(CCCN7CCCC7)=O)c6)ccc5cc4)CC3)=O)c2)c1 Chemical compound CC[n]1c(cccc2)c2c(-c2n[nH]c(NC(CCCN3CCC(CC[n]4c5cc(-c6n[nH]c(NC(CCCN7CCCC7)=O)c6)ccc5cc4)CC3)=O)c2)c1 BLGGXPBHLUZEDW-UHFFFAOYSA-N 0.000 description 1
- IEBQTOHHAVALDV-UHFFFAOYSA-N CC[n]1c2cc(-c3n[nH]c(NC(CCCN4CC(CC[n](ccc5c6)c5ccc6-c5n[nH]c(NC(CCCN6CCCCC6)=O)c5)CCC4)=O)c3)ccc2cc1 Chemical compound CC[n]1c2cc(-c3n[nH]c(NC(CCCN4CC(CC[n](ccc5c6)c5ccc6-c5n[nH]c(NC(CCCN6CCCCC6)=O)c5)CCC4)=O)c3)ccc2cc1 IEBQTOHHAVALDV-UHFFFAOYSA-N 0.000 description 1
- QDGLSADWFSXUBY-UHFFFAOYSA-N COc(cc1)ncc1-c1n[nH]c(NC(CCCC2CCCCCC2)=O)c1 Chemical compound COc(cc1)ncc1-c1n[nH]c(NC(CCCC2CCCCCC2)=O)c1 QDGLSADWFSXUBY-UHFFFAOYSA-N 0.000 description 1
- LQZCUVGTGAEKRA-LMUZMDBKSA-N C[C@@H]1N(CCCC(Nc2cc(-c(cc3)cc4c3nc(C3CN(CCCC(Nc5cc(-c6cnc(C)cc6)n[nH]5)=O)CC3)cc4)n[nH]2)=O)CCCC1 Chemical compound C[C@@H]1N(CCCC(Nc2cc(-c(cc3)cc4c3nc(C3CN(CCCC(Nc5cc(-c6cnc(C)cc6)n[nH]5)=O)CC3)cc4)n[nH]2)=O)CCCC1 LQZCUVGTGAEKRA-LMUZMDBKSA-N 0.000 description 1
- HOMQRFKEQCILAS-UHFFFAOYSA-N Cc(cc1)nc(cc2)c1cc2-c1n[nH]c(NC(CCCN2CCCC2)=O)c1 Chemical compound Cc(cc1)nc(cc2)c1cc2-c1n[nH]c(NC(CCCN2CCCC2)=O)c1 HOMQRFKEQCILAS-UHFFFAOYSA-N 0.000 description 1
- NJFKQPHGDREVOZ-UHFFFAOYSA-N Cc(nc(C(F)(F)F)cc1)c1-c1cc(NC(CCCN(CC2)CCC2c2ccc(cc(cc3)-c4n[nH]c(NC(CCCN5CCCC5)=O)c4)c3n2)=O)n[nH]1 Chemical compound Cc(nc(C(F)(F)F)cc1)c1-c1cc(NC(CCCN(CC2)CCC2c2ccc(cc(cc3)-c4n[nH]c(NC(CCCN5CCCC5)=O)c4)c3n2)=O)n[nH]1 NJFKQPHGDREVOZ-UHFFFAOYSA-N 0.000 description 1
- YZKPEZRDOHWTMW-WBDTVUNHSA-N N/C(/NC(CCCN1CCCCC1)=O)=C\C(c(cc1)c[n]2c1cnc2)=N Chemical compound N/C(/NC(CCCN1CCCCC1)=O)=C\C(c(cc1)c[n]2c1cnc2)=N YZKPEZRDOHWTMW-WBDTVUNHSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- VWQBSZXPQBSWMY-UHFFFAOYSA-N O=C(CCCN1CCCC1)Nc1cc(-c2cc(cccc3)c3nc2)n[nH]1 Chemical compound O=C(CCCN1CCCC1)Nc1cc(-c2cc(cccc3)c3nc2)n[nH]1 VWQBSZXPQBSWMY-UHFFFAOYSA-N 0.000 description 1
- PVGZAVBHVKFGHJ-UHFFFAOYSA-N O=C(CCCN1CCCCC1)NC(C1)NN=C1c1cncc([F]/[O]=C(/C=C2)\N(C(F)F)C=C2c2n[nH]c(NC(CCCN3CCCCC3)=O)c2)c1 Chemical compound O=C(CCCN1CCCCC1)NC(C1)NN=C1c1cncc([F]/[O]=C(/C=C2)\N(C(F)F)C=C2c2n[nH]c(NC(CCCN3CCCCC3)=O)c2)c1 PVGZAVBHVKFGHJ-UHFFFAOYSA-N 0.000 description 1
- CDZATIIGKUMVHU-UHFFFAOYSA-N O=C(CCCN1CCCCC1)Nc1cc(-c2c(cccc3)[n]3nc2)n[nH]1 Chemical compound O=C(CCCN1CCCCC1)Nc1cc(-c2c(cccc3)[n]3nc2)n[nH]1 CDZATIIGKUMVHU-UHFFFAOYSA-N 0.000 description 1
- AEYZDDZERKIIAB-UHFFFAOYSA-N O=C(CCCN1CCCCC1)Nc1n[nH]c(-c2cnc(C(F)(F)F)cc2)c1 Chemical compound O=C(CCCN1CCCCC1)Nc1n[nH]c(-c2cnc(C(F)(F)F)cc2)c1 AEYZDDZERKIIAB-UHFFFAOYSA-N 0.000 description 1
- 102000015296 acetylcholine-gated cation-selective channel activity proteins Human genes 0.000 description 1
- 108040006409 acetylcholine-gated cation-selective channel activity proteins Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8121108P | 2008-07-16 | 2008-07-16 | |
| US61/081,211 | 2008-07-16 | ||
| PCT/US2009/050797 WO2010009290A1 (en) | 2008-07-16 | 2009-07-16 | Alpha7 nicotinic acetylcholine receptor inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011528372A JP2011528372A (ja) | 2011-11-17 |
| JP2011528372A5 true JP2011528372A5 (enExample) | 2012-07-19 |
Family
ID=41137861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011518900A Pending JP2011528372A (ja) | 2008-07-16 | 2009-07-16 | α７ニコチン性アセチルコリンレセプターインヒビター |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100130474A1 (enExample) |
| EP (1) | EP2323988A1 (enExample) |
| JP (1) | JP2011528372A (enExample) |
| AR (1) | AR072508A1 (enExample) |
| CA (1) | CA2729606A1 (enExample) |
| PA (1) | PA8836101A1 (enExample) |
| TW (1) | TW201004941A (enExample) |
| WO (1) | WO2010009290A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008000119A1 (es) | 2007-01-16 | 2008-05-16 | Wyeth Corp | Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia. |
| US8841329B2 (en) | 2008-09-11 | 2014-09-23 | Dignity Health | Nicotinic attenuation of CNS inflammation and autoimmunity |
| EP2560966B1 (en) | 2010-03-30 | 2021-01-06 | Verseon International Corporation | Multisubstituted aromatic compounds as inhibitors of thrombin |
| ES2651002T3 (es) | 2010-04-16 | 2018-01-23 | Bayer Intellectual Property Gmbh | Nuevos compuestos heterocíclicos como pesticidas |
| CN105360131A (zh) * | 2010-11-03 | 2016-03-02 | 陶氏益农公司 | 杀虫组合物和与其相关的方法 |
| CA2852688C (en) | 2011-10-26 | 2021-06-29 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| US9708288B2 (en) | 2012-04-27 | 2017-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| US9282739B2 (en) | 2012-04-27 | 2016-03-15 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| NZ700595A (en) | 2012-04-27 | 2016-04-29 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| US20150313884A1 (en) | 2013-01-15 | 2015-11-05 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
| CA2925873A1 (en) | 2013-10-17 | 2015-04-23 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| MX2016004942A (es) | 2013-10-17 | 2016-06-28 | Dow Agrosciences Llc | Procesos para la preparacion de compuestos plaguicidas. |
| CN105636442B (zh) | 2013-10-17 | 2018-04-27 | 美国陶氏益农公司 | 制备杀虫化合物的方法 |
| CA2925952A1 (en) | 2013-10-17 | 2015-04-23 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| JP2016536295A (ja) | 2013-10-17 | 2016-11-24 | ダウ アグロサイエンシィズ エルエルシー | 有害生物防除性化合物の製造方法 |
| KR20160074540A (ko) | 2013-10-17 | 2016-06-28 | 다우 아그로사이언시즈 엘엘씨 | 살충성 화합물의 제조 방법 |
| CN105636445B (zh) | 2013-10-17 | 2018-12-07 | 美国陶氏益农公司 | 制备杀虫化合物的方法 |
| WO2015061146A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
| MX2016005310A (es) | 2013-10-22 | 2016-08-08 | Dow Agrosciences Llc | Composiciones pesticidas sinergicas y metodos relacionados. |
| WO2015061148A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
| AU2014340416B2 (en) | 2013-10-22 | 2017-09-07 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
| JP2016534076A (ja) | 2013-10-22 | 2016-11-04 | ダウ アグロサイエンシィズ エルエルシー | 相乗的有害生物防除組成物および関連する方法 |
| CA2927220A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
| CA2926433A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
| KR102275655B1 (ko) | 2013-10-22 | 2021-07-09 | 코르테바 애그리사이언스 엘엘씨 | 살충 조성물 및 관련 방법 |
| CN105828612A (zh) | 2013-10-22 | 2016-08-03 | 美国陶氏益农公司 | 协同杀虫组合物和相关方法 |
| AR098091A1 (es) | 2013-10-22 | 2016-05-04 | Dow Agrosciences Llc | Composiciones pesticidas sinérgicas y métodos relacionados |
| WO2015061163A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
| KR102286233B1 (ko) | 2013-10-22 | 2021-08-06 | 코르테바 애그리사이언스 엘엘씨 | 살충 조성물 및 관련 방법 |
| US9549560B2 (en) | 2013-10-22 | 2017-01-24 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
| CA2926345A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
| WO2015061165A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
| NZ719776A (en) | 2013-10-22 | 2017-06-30 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
| AR098097A1 (es) | 2013-10-22 | 2016-05-04 | Dow Agrosciences Llc | Composiciones plaguicidas sinérgicas y métodos relacionados |
| KR20170005868A (ko) | 2014-05-23 | 2017-01-16 | 액티브 바이오테크 에이비 | S100-저해제로서 유용한 새로운 화합물 |
| MX2014006541A (es) * | 2014-05-30 | 2015-11-30 | Univ Autonoma Del Estado De Morelos | Sintesis de analogos y-aminoacidos y productos obtenidos. |
| JP2017523163A (ja) | 2014-07-31 | 2017-08-17 | ダウ アグロサイエンシィズ エルエルシー | ３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの製造方法 |
| AR098108A1 (es) | 2014-07-31 | 2016-05-04 | Dow Agrosciences Llc | Proceso para la preparación de 3-(3-cloro-1h-pirazol-1-il)piridina |
| EP3186229A4 (en) | 2014-07-31 | 2018-01-10 | Dow AgroSciences LLC | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
| CN107074774A (zh) | 2014-08-19 | 2017-08-18 | 美国陶氏益农公司 | 制备3‑(3‑氯‑1h‑吡唑‑1‑基)吡啶的方法 |
| WO2016039781A1 (en) | 2014-09-12 | 2016-03-17 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
| US10532995B2 (en) | 2015-02-27 | 2020-01-14 | Verseon Corporation | Substituted pyrazole compounds as serine protease inhibitors |
| CN110139853B (zh) | 2016-12-29 | 2023-06-16 | 美国陶氏益农公司 | 用于制备杀有害生物化合物的方法 |
| CN110325036B (zh) | 2016-12-29 | 2021-10-26 | 美国陶氏益农公司 | 用于制备杀虫化合物的方法 |
| CN112457255B (zh) * | 2017-11-08 | 2022-08-19 | 北京嘉林药业股份有限公司 | 化合物及其治疗癌症的用途 |
| CN109134406A (zh) * | 2018-08-02 | 2019-01-04 | 丽珠集团新北江制药股份有限公司 | 一种布瓦西坦中间体及布瓦西坦的合成方法 |
| TWI904906B (zh) | 2020-08-24 | 2025-11-11 | 美商達薩瑪治療公司 | Sarm1之抑制劑 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007098826A2 (en) * | 2006-01-18 | 2007-09-07 | Siena Biotech S.P.A. | Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof |
| CL2008000119A1 (es) * | 2007-01-16 | 2008-05-16 | Wyeth Corp | Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia. |
-
2009
- 2009-06-30 TW TW098122040A patent/TW201004941A/zh unknown
- 2009-07-14 AR ARP090102661A patent/AR072508A1/es not_active Application Discontinuation
- 2009-07-16 CA CA2729606A patent/CA2729606A1/en not_active Abandoned
- 2009-07-16 WO PCT/US2009/050797 patent/WO2010009290A1/en not_active Ceased
- 2009-07-16 EP EP09790514A patent/EP2323988A1/en not_active Withdrawn
- 2009-07-16 PA PA20098836101A patent/PA8836101A1/es unknown
- 2009-07-16 JP JP2011518900A patent/JP2011528372A/ja active Pending
- 2009-07-16 US US12/503,997 patent/US20100130474A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011528372A5 (enExample) | ||
| JP7263266B2 (ja) | ジヒドロ－ピロロ－ピリジン誘導体 | |
| JP5537084B2 (ja) | アリールビニルアザシクロアルカン化合物およびその調製方法ならびにその使用 | |
| EA201001696A1 (ru) | СОЕДИНЕНИЯ ХИНУКЛИДИНА В КАЧЕСТВЕ ЛИГАНДОВ НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА α7 | |
| JP6505023B2 (ja) | Ｃｎｓおよび他の障害を治療するための、ｐｄｅ４アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物 | |
| JP2019519583A (ja) | 神経性疾患および神経変性疾患を処置するための５，７−ジヒドロピロロピリジン誘導体 | |
| TW200531689A (en) | Therapeutic agents | |
| NO20073300L (no) | Glycintransportinhibitorer | |
| WO2014080290A2 (en) | Cyclic amines as bromodomain inhibitors | |
| EG26020A (en) | Derivatives 3- (Hetero Aryl-AXY) -2- Alkyl -1- AZA Dicyclic Alkyl Carbides Alpha 7- NACHR for the treatment of diseases of the central nervous system | |
| JP2016516791A (ja) | Ｌｒｒｋ２阻害剤としてのアリールピロロピリジン誘導化合物 | |
| TW200635903A (en) | Therapeutic agents | |
| NO20070347L (no) | Modulatorer av alfa7 nikotinske acetylkolinreseptorer og terapeutiske anvendelser | |
| TW200504034A (en) | Therapeutic agents | |
| JP2019534327A5 (enExample) | ||
| JP2017523213A (ja) | 抗菌薬としてのキノロン誘導体 | |
| JP2012097115A5 (enExample) | ||
| JP2003500402A (ja) | 中枢神経系薬として有用なアミノアザ環のヘテロ環置換体 | |
| EA201390712A1 (ru) | Производные пиридазина, композиции и способы лечения когнитивного нарушения | |
| EA023293B1 (ru) | ЛИГАНДЫ НЕЙРОНАЛЬНОГО НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА αβ | |
| JP2023502857A (ja) | Ｌｒｒｋ２阻害薬としてのｎ－（ヘテロアリール）キナゾリン－２－アミン誘導体、医薬組成物及びその使用 | |
| TW200633986A (en) | Therapeutic agents | |
| JP2005537297A (ja) | アルファ−７ｎａｃｈｒ活性を有する１ｈ−ピラゾールおよび１ｈ−ピロール−アザビシクロ化合物 | |
| JP2006519868A5 (enExample) | ||
| CN108699080B (zh) | 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物 |